AC Immune Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van AC Immune is gedaald met een gemiddeld jaarlijks percentage van -20.2%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 7.7%. De inkomsten zijn daalde met een gemiddeld percentage van 52.3% per jaar.

Belangrijke informatie

-20.2%

Groei van de winst

-17.0%

Groei van de winst per aandeel

Biotechs Groei van de industrie	-14.6%
Inkomstengroei	-52.3%
Rendement op eigen vermogen	-30.6%
Nettomarge	-97.3%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe AC Immune geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

DB:IMR Opbrengsten, kosten en inkomsten (CHF Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Sep 24	41	-40	17
30 Jun 24	15	-61	17
31 Mar 24	15	-55	16
31 Dec 23	15	-54	15
30 Sep 23	0	-68	15
30 Jun 23	4	-67	15
31 Mar 23	4	-69	16
31 Dec 22	4	-71	16
30 Sep 22	4	-73	14
30 Jun 22	0	-76	16
31 Mar 22	0	-75	17
31 Dec 21	0	-73	18
30 Sep 21	1	-71	19
30 Jun 21	2	-74	19
31 Mar 21	3	-71	18
31 Dec 20	15	-62	19
30 Sep 20	15	-62	19
30 Jun 20	47	-25	18
31 Mar 20	48	-26	17
31 Dec 19	110	45	16
30 Sep 19	111	50	15
30 Jun 19	80	18	14
31 Mar 19	81	24	13
31 Dec 18	7	-51	12
30 Sep 18	22	-32	12
30 Jun 18	21	-27	11
31 Mar 18	20	-29	10
31 Dec 17	20	-26	10
30 Sep 17	5	-35	10
30 Jun 17	6	-36	10
31 Mar 17	25	-10	9
31 Dec 16	23	-7	8
30 Sep 16	22	-8	5
30 Jun 16	45	21	4
31 Mar 16	39	17	4
31 Dec 15	39	20	3
30 Sep 15	65	46	4
30 Jun 15	41	21	4
31 Mar 15	28	10	3
31 Dec 14	30	11	3
31 Dec 13	9	-11	3

Kwaliteitswinsten: IMR is momenteel verliesgevend.

Groeiende winstmarge: IMR is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: IMR is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 20.2% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van IMR over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: IMR is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -18.2% ).

Rendement op eigen vermogen

Hoge ROE: IMR heeft een negatief Return on Equity ( -30.63% ), omdat het momenteel verliesgevend is.

AC Immune Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2023 earnings released: CHF0.64 loss per share (vs CHF0.85 loss in FY 2022)

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

Third quarter 2020 earnings released: CHF0.26 loss per share

First half earnings released

Recent updates

Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease

Insufficient new directors

No longer forecast to breakeven

New minor risk - Profitability

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

New major risk - Revenue and earnings growth

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Forecast to breakeven in 2025

Forecast to breakeven in 2026

Full year 2023 earnings released: CHF0.64 loss per share (vs CHF0.85 loss in FY 2022)

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

New major risk - Revenue and earnings growth

AC Immune SA Announces Executive Changes

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

AC Immune SA Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

New 90-day high: €5.57

Ac Immune Reports Progress for Therapeutic Programs Targeting the Nlrp3 Inflammasome Pathway

New 90-day high: €5.17

AC Immune SA Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

AC Immune Sa Appoints Carl H. June as Board of Directors

AC Immune SA Hires Johannes R. Streffer as Chief Medical Officer

Revenue beats expectations

Third quarter 2020 earnings released: CHF0.26 loss per share

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

New 90-day low: €3.83

AC Immune SA Announces EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease

New 90-day low: €4.25

First half earnings released

New 90-day high - €7.95

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden